Figure 1. Flow Chart of This Study. Baseline assessments were performed prior to the initial administration of semaglutide (0.25 mg). After patients received semaglutide 1.0 mg for 180 days, their weights were measured. OHA, oral hypoglycemic agent.
Figure 2. Receiver-operating characteristic curve analysis. Receiver-operating characteristic curve analysis was used to identify the optimal pretreatment level of HDL cholesterol for the presence of greater response in weight reduction after weekly treatment with 1.0 mg semaglutide. This cutoff value, based on the sensitivity and specificity values, was calculated as 46 mg/dL (area under the curve, 0.64; standard error, 0.05; 95% confidence interval, 0.51-0.77; p = 0.03). HDL, high-density lipoprotein.
